Update on treatment of pulmonary exacerbations in cystic fibrosis

被引:25
作者
Smyth, Alan [1 ]
机构
[1] City Hosp Nottingham, Div Resp Med, Nottingham MG5 1PB, England
关键词
cystic fibrosis; Pseudomonas aeruginosa; pulmonary exacerbations;
D O I
10.1097/01.mcp.0000245711.43891.16
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of review This review will define pulmonary exacerbations in cystic fibrosis and explain their importance in the pathophysiology and progression of this condition. I will stress the importance of prevention, where this is possible, and prompt treatment, where prevention has failed. The management of chronic pulmonary infection with Pseudomonas aeruginosa will be discussed, together with other, less tenacious organisms. Recent findings Developments in the treatment of chronic pulmonary infection with P. aeruginosa include new data on antibiotic selection through sensitivity testing and alternative antibiotic dosing regimens. Therapies which target the P. aeruginosa biofilm will be discussed, including those which are currently in use (such as azithromycin) as well as those being evaluated in preclinical studies. Supportive care and the role of noninvasive ventilation are discussed. Summary The prevention and prompt treatment of pulmonary exacerbations is a central component of cystic fibrosis care.
引用
收藏
页码:440 / 444
页数:5
相关论文
共 41 条
[31]   A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities [J].
Quan, JM ;
Tiddens, HAWM ;
Sy, JP ;
McKenzie, SG ;
Montgomery, MD ;
Robinson, PJ ;
Wohl, MEB ;
Konstan, MW .
JOURNAL OF PEDIATRICS, 2001, 139 (06) :813-820
[32]   Intermittent administration of inhaled tobramycin in patients with cystic fibrosis [J].
Ramsey, BW ;
Pepe, MS ;
Quan, JM ;
Otto, KL ;
Montgomery, AB ;
Williams-Warren, J ;
Vasiljev-K, M ;
Borowitz, D ;
Bowman, CM ;
Marshall, BC ;
Marshall, S ;
Smith, AL .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (01) :23-30
[33]   Defining a pulmonary exacerbation in cystic fibrosis [J].
Rosenfeld, M ;
Emerson, J ;
Williams-Warren, J ;
Pepe, M ;
Smith, A ;
Montgomery, AB ;
Ramsey, B .
JOURNAL OF PEDIATRICS, 2001, 139 (03) :359-365
[34]   Azithromycin in, patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa -: A randomized controlled trial [J].
Saiman, L ;
Marshall, BC ;
Mayer-Hamblett, N ;
Burns, JL ;
Quittner, AL ;
Cibene, DA ;
Coquillette, S ;
Fieberg, AY ;
Accurso, FJ ;
Campbel, PW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (13) :1749-1756
[35]   Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis [J].
Slieker, MG ;
van Gestel, JPJ ;
Heijerman, HGM ;
Tramper-Stranders, GA ;
van Berkhout, FT ;
van der Ent, CK ;
Jansen, NJG .
INTENSIVE CARE MEDICINE, 2006, 32 (05) :754-758
[36]   Objective measurement of cough during pulmonary exacerbations in adults with cystic fibrosis [J].
Smith, JA ;
Owen, EC ;
Jones, AM ;
Dodd, ME ;
Webb, AK ;
Woodcock, A .
THORAX, 2006, 61 (05) :425-429
[37]   Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial [J].
Smyth, A ;
Tan, KHV ;
Hyman-Taylor, P ;
Mulheran, M ;
Lewis, S ;
Stableforth, D ;
Knox, A .
LANCET, 2005, 365 (9459) :573-578
[38]  
UK CF Trust, 2005, UK CYST FIBR DAT ANN
[39]   How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? [J].
VanDevanter, DR ;
Van Dalfsen, JM .
PEDIATRIC PULMONOLOGY, 2005, 39 (06) :504-506
[40]  
VANEWIJK B, 2006, J CYST FIBROS, V5, pS15